Medilink Therapeutics Raises $ 50 Million in Series A Funding to Accelerate Research and Development of Next-Generation Conjugate Drugs
SUJOU, China, March 1, 2021 / PRNewswire / - Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotechnology company focused on the research and development of next-generation antibody-drug conjugates, a...